Skip to main content
Fig. 8 | Cancer Nanotechnology

Fig. 8

From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers

Fig. 8

In vivo antitumor efficacy in an OVCAR3-xenografted mouse model following intravenous injection of different formulations at a dose of 5 mg docetaxel (DTX)-equivalent/kg on days 0, 7, and 14, a total of three injections per mouse. A Changes in tumor volume for 28 days of post-administration and TGI calculated by Eq. 7. B Changes in body weight. C Survival curves. D Representative images of excised tumors. Scale bar indicates 10 mm. Data represent mean ± SD (n = 4)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us